Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een NIS ter evaluatie van injecteerbare behandelingen bij patiënten met recidiverende multiple sclerose (AIOLOS)

13 november 2026 bijgewerkt door: Novartis Pharmaceuticals

Een niet-interventionele studie ter evaluatie van injecteerbare behandelingen (ofatumumab, glatirameeracetaat en interferon β1) bij patiënten met recidiverende multiple sclerose [AIOLOS]

This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany.

Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses.

Studie Overzicht

Gedetailleerde beschrijving

The prerequisite for participation in this observational study is the independent decision of the treating physician and patient to start an approved injectable or oral DMT for RMS as routine medical treatment. This decision must have been made prior to enrollment in this study.

Cohort 1: The prospective observational period per patient in the core part will be up to approx. two years from the time of consent (2 years +2 months visit window). If a patient re-consents to the extension part, then the prospective extension observational period will be additional approx. two years, resulting in a total observational period (prospectively for the core and extension part & retrospectively for the potential gap between core and extension part) of approx. 4 years (+ 2 month visit window).

Cohort 2: The prospective observational period per patient will be up to approx. two years from the time of consent (2 years + 2 months visit window).

The observational period will not be dictated by the protocol. The follow-up documentation will take place at a frequency defined as per investigator's discretion. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care, can be performed as telemedicine visits and will take place as per investigator's discretion.

Studietype

Observationeel

Inschrijving (Geschat)

800

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

  • Naam: Novartis Pharmaceuticals

Studie Locaties

      • Aalen, Duitsland, 73433
        • Werving
        • Novartis Investigative Site
      • Altenholz, Duitsland, 24161
        • Werving
        • Novartis Investigative Site
      • Alzey, Duitsland, 55232
        • Ingetrokken
        • Novartis Investigative Site
      • Augsburg, Duitsland, 86150
        • Werving
        • Novartis Investigative Site
      • Bamberg, Duitsland, 96047
        • Actief, niet wervend
        • Novartis Investigative Site
      • Bayreuth, Duitsland, 95445
        • Actief, niet wervend
        • Novartis Investigative Site
      • Bayreuth, Duitsland, 95444
        • Werving
        • Novartis Investigative Site
      • Bergneustadt, Duitsland, 51702
        • Werving
        • Novartis Investigative Site
      • Bergneustadt, Duitsland, 51702
        • Ingetrokken
        • Novartis Investigative Site
      • Berlin, Duitsland, 12163
        • Werving
        • Novartis Investigative Site
      • Berlin, Duitsland, 12099
        • Werving
        • Novartis Investigative Site
      • Berlin, Duitsland, 14057
        • Werving
        • Novartis Investigative Site
      • Berlin, Duitsland, 10437
        • Actief, niet wervend
        • Novartis Investigative Site
      • Berlin, Duitsland, 10713
        • Actief, niet wervend
        • Novartis Investigative Site
      • Berlin, Duitsland, 12099
        • Actief, niet wervend
        • Novartis Investigative Site
      • Berlin, Duitsland, 12099
        • Voltooid
        • Novartis Investigative Site
      • Berlin, Duitsland, 12351
        • Voltooid
        • Novartis Investigative Site
      • Berlin, Duitsland, 13357
        • Ingetrokken
        • Novartis Investigative Site
      • Berlin, Duitsland, 14169
        • Actief, niet wervend
        • Novartis Investigative Site
      • Bochum, Duitsland, 44791
        • Werving
        • Novartis Investigative Site
      • Bochum, Duitsland, 44787
        • Werving
        • Novartis Investigative Site
      • Bogen, Duitsland, 94327
        • Werving
        • Novartis Investigative Site
      • Bonn, Duitsland, 53111
        • Werving
        • Novartis Investigative Site
      • Braunschweig, Duitsland, 38100
        • Werving
        • Novartis Investigative Site
      • Bremen, Duitsland, 28195
        • Voltooid
        • Novartis Investigative Site
      • Böblingen, Duitsland, 71032
        • Werving
        • Novartis Investigative Site
      • Chemnitz, Duitsland, 09117
        • Werving
        • Novartis Investigative Site
      • Coburg, Duitsland, 96450
        • Werving
        • Novartis Investigative Site
      • Crailsheim, Duitsland, 74564
        • Werving
        • Novartis Investigative Site
      • Dessau, Duitsland, 06846
        • Actief, niet wervend
        • Novartis Investigative Site
      • Dillingen Saar, Duitsland, 66763
        • Werving
        • Novartis Investigative Site
      • Dortmund, Duitsland, 44137
        • Werving
        • Novartis Investigative Site
      • Dresden, Duitsland, 01067
        • Actief, niet wervend
        • Novartis Investigative Site
      • Dresden, Duitsland, 01097
        • Werving
        • Novartis Investigative Site
      • Duisburg, Duitsland, 47138
        • Werving
        • Novartis Investigative Site
      • Duisburg, Duitsland, 47138
        • Ingetrokken
        • Novartis Investigative Site
      • Düsseldorf, Duitsland, 40211
        • Werving
        • Novartis Investigative Site
      • Düsseldorf, Duitsland, 40625
        • Werving
        • Novartis Investigative Site
      • Düsseldorf, Duitsland, 40211
        • Voltooid
        • Novartis Investigative Site
      • Eisleben Lutherstadt, Duitsland, 06295
        • Werving
        • Novartis Investigative Site
      • Eltville, Duitsland, 65343
        • Werving
        • Novartis Investigative Site
      • Erbach im Odenwald, Duitsland, 64711
        • Werving
        • Novartis Investigative Site
      • Erfurt, Duitsland, 99099
        • Werving
        • Novartis Investigative Site
      • Erfurt, Duitsland, 99096
        • Werving
        • Novartis Investigative Site
      • Erlangen, Duitsland, 91054
        • Werving
        • Novartis Investigative Site
      • Essen, Duitsland, 45257
        • Werving
        • Novartis Investigative Site
      • Essen, Duitsland, 45138
        • Werving
        • Novartis Investigative Site
      • Fulda, Duitsland, 36037
        • Werving
        • Novartis Investigative Site
      • Fulda, Duitsland, 36037
        • Voltooid
        • Novartis Investigative Site
      • Giessen, Duitsland, 35392
        • Werving
        • Novartis Investigative Site
      • Gladenbach, Duitsland, 35075
        • Werving
        • Novartis Investigative Site
      • Hagen, Duitsland, 58095
        • Actief, niet wervend
        • Novartis Investigative Site
      • Hamburg, Duitsland, 20249
        • Werving
        • Novartis Investigative Site
      • Hamburg, Duitsland, 22179
        • Werving
        • Novartis Investigative Site
      • Hanover, Duitsland, 30625
        • Werving
        • Novartis Investigative Site
      • Höxter, Duitsland, 37671
        • Werving
        • Novartis Investigative Site
      • Itzehoe, Duitsland, 25524
        • Ingetrokken
        • Novartis Investigative Site
      • Kaiserslautern, Duitsland, 67655
        • Voltooid
        • Novartis Investigative Site
      • Karlsruhe, Duitsland, 76133
        • Werving
        • Novartis Investigative Site
      • Karlsruhe, Duitsland, 76133
        • Ingetrokken
        • Novartis Investigative Site
      • Lünen, Duitsland, 44534
        • Ingetrokken
        • Novartis Investigative Site
      • Magdeburg, Duitsland, 39104
        • Werving
        • Novartis Investigative Site
      • Marburg, Duitsland, 35037
        • Voltooid
        • Novartis Investigative Site
      • Merzig, Duitsland, 66663
        • Werving
        • Novartis Investigative Site
      • Mettmann, Duitsland, 40822
        • Voltooid
        • Novartis Investigative Site
      • Minden, Duitsland, 32429
        • Voltooid
        • Novartis Investigative Site
      • Montabaur, Duitsland, 56410
        • Voltooid
        • Novartis Investigative Site
      • Muenster-Hiltrup, Duitsland, 48165
        • Werving
        • Novartis Investigative Site
      • Mülheim, Duitsland, 45468
        • Ingetrokken
        • Novartis Investigative Site
      • München, Duitsland, 80939
        • Werving
        • Novartis Investigative Site
      • München, Duitsland, 81675
        • Actief, niet wervend
        • Novartis Investigative Site
      • Münster, Duitsland, 48149
        • Werving
        • Novartis Investigative Site
      • Neuruppin, Duitsland, 16816
        • Actief, niet wervend
        • Novartis Investigative Site
      • Nuremberg, Duitsland, 90491
        • Ingetrokken
        • Novartis Investigative Site
      • Oldenburg, Duitsland, 26121
        • Werving
        • Novartis Investigative Site
      • Osnabrück, Duitsland, 49074
        • Werving
        • Novartis Investigative Site
      • Pforzheim, Duitsland, 75172
        • Werving
        • Novartis Investigative Site
      • Potsdam, Duitsland, 14471
        • Voltooid
        • Novartis Investigative Site
      • Remscheid, Duitsland, 42853
        • Werving
        • Novartis Investigative Site
      • Rostock, Duitsland, 18057
        • Voltooid
        • Novartis Investigative Site
      • Rüdersdorf, Duitsland, 15562
        • Actief, niet wervend
        • Novartis Investigative Site
      • Rülzheim, Duitsland, 76761
        • Werving
        • Novartis Investigative Site
      • Salzatal, Duitsland, 06198
        • Werving
        • Novartis Investigative Site
      • Schiltach, Duitsland, 77761
        • Werving
        • Novartis Investigative Site
      • Schneverdingen, Duitsland, 29640
        • Werving
        • Novartis Investigative Site
      • Siegen, Duitsland, 57076
        • Actief, niet wervend
        • Novartis Investigative Site
      • Siegen, Duitsland, 57076
        • Werving
        • Novartis Investigative Site
      • Sinsheim, Duitsland, 74889
        • Werving
        • Novartis Investigative Site
      • Stadtroda, Duitsland, 07646
        • Werving
        • Novartis Investigative Site
      • Stuttgart, Duitsland, 70176
        • Werving
        • Novartis Investigative Site
      • Stuttgart, Duitsland, 70174
        • Actief, niet wervend
        • Novartis Investigative Site
      • Stuttgart, Duitsland, 70182
        • Voltooid
        • Novartis Investigative Site
      • Tirschenreuth, Duitsland, 95643
        • Werving
        • Novartis Investigative Site
      • Trier, Duitsland, 54292
        • Werving
        • Novartis Investigative Site
      • Tübingen, Duitsland, 72076
        • Werving
        • Novartis Investigative Site
      • Velbert, Duitsland, 42551
        • Werving
        • Novartis Investigative Site
      • Weil der Stadt, Duitsland, 71263
        • Werving
        • Novartis Investigative Site
      • Witten, Duitsland, 58452
        • Werving
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Albstadt, Baden-Wurttemberg, Duitsland, 72458
        • Werving
        • Novartis Investigative Site
      • Hettingen, Baden-Wurttemberg, Duitsland, 72513
        • Werving
        • Novartis Investigative Site
      • Hettingen, Baden-Wurttemberg, Duitsland, 72513
        • Voltooid
        • Novartis Investigative Site
      • Mannheim, Baden-Wurttemberg, Duitsland, 68163
        • Werving
        • Novartis Investigative Site
      • Nagold, Baden-Wurttemberg, Duitsland, 72202
        • Werving
        • Novartis Investigative Site
      • Schwetzingen, Baden-Wurttemberg, Duitsland, 68723
        • Werving
        • Novartis Investigative Site
      • Schwäbisch Hall, Baden-Wurttemberg, Duitsland, 74523
        • Werving
        • Novartis Investigative Site
    • Bavaria
      • Bamberg, Bavaria, Duitsland, 96052
        • Actief, niet wervend
        • Novartis Investigative Site
      • Dillingen an der Donau, Bavaria, Duitsland, 89407
        • Actief, niet wervend
        • Novartis Investigative Site
      • Munich, Bavaria, Duitsland, 81241
        • Ingetrokken
        • Novartis Investigative Site
      • Munich, Bavaria, Duitsland, 81829
        • Ingetrokken
        • Novartis Investigative Site
      • Neuburg A.d. Donau, Bavaria, Duitsland, 86633
        • Actief, niet wervend
        • Novartis Investigative Site
      • Regensburg, Bavaria, Duitsland, 93059
        • Ingetrokken
        • Novartis Investigative Site
      • Unterhaching, Bavaria, Duitsland, 82008
        • Actief, niet wervend
        • Novartis Investigative Site
      • Untermeitingen, Bavaria, Duitsland, 86836
        • Werving
        • Novartis Investigative Site
      • Wolfratshausen, Bavaria, Duitsland, 82515
        • Ingetrokken
        • Novartis Investigative Site
    • Brandenburg
      • Falkensee, Brandenburg, Duitsland, 14612
        • Ingetrokken
        • Novartis Investigative Site
    • Hesse
      • Bad Homburg, Hesse, Duitsland, 61348
        • Werving
        • Novartis Investigative Site
      • Frankfurt am Main, Hesse, Duitsland, 65929
        • Actief, niet wervend
        • Novartis Investigative Site
      • Frankfurt am Main, Hesse, Duitsland, 60313
        • Voltooid
        • Novartis Investigative Site
      • Marburg, Hesse, Duitsland, 35043
        • Actief, niet wervend
        • Novartis Investigative Site
    • Lower Saxony
      • Hanover, Lower Saxony, Duitsland, 30161
        • Actief, niet wervend
        • Novartis Investigative Site
      • Hanover, Lower Saxony, Duitsland, 30449
        • Voltooid
        • Novartis Investigative Site
      • Wildeshausen, Lower Saxony, Duitsland, 27793
        • Actief, niet wervend
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Duitsland, 50935
        • Werving
        • Novartis Investigative Site
      • Cologne, North Rhine-Westphalia, Duitsland, 51063
        • Ingetrokken
        • Novartis Investigative Site
      • Dortmund, North Rhine-Westphalia, Duitsland, 44287
        • Werving
        • Novartis Investigative Site
      • Düsseldorf, North Rhine-Westphalia, Duitsland, 40225
        • Werving
        • Novartis Investigative Site
      • Essen, North Rhine-Westphalia, Duitsland, 45134
        • Ingetrokken
        • Novartis Investigative Site
      • Gelsenkirchen, North Rhine-Westphalia, Duitsland, 45894
        • Werving
        • Novartis Investigative Site
      • Meerbusch, North Rhine-Westphalia, Duitsland, 40667
        • Werving
        • Novartis Investigative Site
      • Münster, North Rhine-Westphalia, Duitsland, 48165
        • Ingetrokken
        • Novartis Investigative Site
      • Oer-Erkenschwick, North Rhine-Westphalia, Duitsland, 45739
        • Ingetrokken
        • Novartis Investigative Site
      • Siegen, North Rhine-Westphalia, Duitsland, 57072
        • Actief, niet wervend
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Ingelheim, Rhineland-Palatinate, Duitsland, 55218
        • Ingetrokken
        • Novartis Investigative Site
    • Saarland
      • Saarlouis, Saarland, Duitsland, 66740
        • Ingetrokken
        • Novartis Investigative Site
    • Saxony
      • Chemnitz, Saxony, Duitsland, 09117
        • Actief, niet wervend
        • Novartis Investigative Site
      • Dresden, Saxony, Duitsland, 01307
        • Werving
        • Novartis Investigative Site
      • Görlitz, Saxony, Duitsland, 02828
        • Werving
        • Novartis Investigative Site
      • Leipzig, Saxony, Duitsland, 04103
        • Voltooid
        • Novartis Investigative Site
      • Leipzig, Saxony, Duitsland, 04315
        • Actief, niet wervend
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Altmark, Saxony-Anhalt, Duitsland, 39629
        • Ingetrokken
        • Novartis Investigative Site
      • Halle, Saxony-Anhalt, Duitsland, 06120
        • Werving
        • Novartis Investigative Site
      • Halle, Saxony-Anhalt, Duitsland, 06112
        • Werving
        • Novartis Investigative Site
    • Thuringia
      • Altenburg, Thuringia, Duitsland, 04600
        • Voltooid
        • Novartis Investigative Site
      • Altenburg, Thuringia, Duitsland, 04600
        • Ingetrokken
        • Novartis Investigative Site
      • Jena, Thuringia, Duitsland, 07740
        • Werving
        • Novartis Investigative Site
      • Mühlhausen, Thuringia, Duitsland, 99974
        • Actief, niet wervend
        • Novartis Investigative Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 100 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

patients with planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment

Beschrijving

Cohort 1 Inclusion Criteria:

  1. Signed informed consent must be obtained prior to participation in the study
  2. Male or female patients aged ≥18 years at enrollment
  3. Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b)
  4. RMS with active disease as defined by Lublin et al. (2014)
  5. Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment
  6. Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive)
  7. Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment

Cohort 2 Inclusion Criteria:

  1. Signed informed consent must be obtained prior to participation,

  2. Male or female patients aged ≥18 years at enrollment,

  3. Diagnosis of MS according to the 2024 revised McDonald criteria (Montalban et al., 2025),

  4. RMS with active disease as defined by Lublin et al. (2014) ,

  5. Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment,

  6. Disability status at enrollment with an EDSS score of 0 to 3.0 (inclusive),

  7. Planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment:

    • Ofatumumab: only naïve patients or patients previously treated with max. one DMT other than ofatumumab
    • IFN-β1, GA, teriflunomide, DMF or DRF: only naïve patients

Cohort 1 Exclusion Criteria:

  1. Patients being treated outside of the approved label
  2. > 5 years since first symptom(s) (leading to MS diagnosis) at enrollment
  3. Previous therapy with any DMT for the treatment of MS prior to enrollment (except within the past 14 days with an approved injectable DMT for MS as routine medical treatment; see Inclusion criteria #7)
  4. Relapse prior to enrollment which has led to a severe deficit relevant to everyday life upon discretion of the investigator after exhaustion of the relapse therapy
  5. Poor recovery from the first two relapses prior to enrollment upon discretion of the investigator
  6. EDSS Functional System Score "Pyramidal Functions" ≥ 2 at enrollment
  7. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab

Cohort 2 Exclusion Criteria:

  1. Patients being treated outside of the approved label,
  2. >5 years since first symptom(s) (leading to MS diagnosis) at enrollment,
  3. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab,
  4. Patients being previously enrolled in cohort 1 are not eligible to be enrolled into cohort 2

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Cohorten en interventies

Groep / Cohort
Interventie / Behandeling
Ofatumumab

Patients treated with ofatumumab

There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.

Standard of Care (SoC)

Patients treated with either interferon β1 (IFN-β1), glatiramer acetate (GA), teriflunomide, dimethyl fumarate (DMF) or diroximel fumarate (DRF)

There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.

There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.

There is no treatment allocation. Patients administered teriflunomide by prescription that have started as routine medical treatment will be enrolled.

There is no treatment allocation. Patients administered dimethyl fumarate (DMF) by prescription that have started as routine medical treatment will be enrolled.

There is no treatment allocation. Patients administered diroximel fumarate (DRF) by prescription that have started as routine medical treatment will be enrolled.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of patients who continue to receive their baseline treatment
Tijdsspanne: Month 24

Proportion of patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)]

Month 24

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of patients who continue to receive their baseline treatment
Tijdsspanne: Month 12

Proportion of patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)]

Month 12
Time to event analysis for retention time on baseline treatment
Tijdsspanne: From Baseline to event, up to 24 months

Time-to-event analysis for retention time on baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)]

From Baseline to event, up to 24 months
Impact of first-line treatment on health economy
Tijdsspanne: Baseline, month 6, month 12, month 18 and month 24

Mean annual health care resource utilization cost, annual direct medical costs, annual direct nonmedical costs and annual indirect costs as measured by MS Health Resource Utilization Survey [MS-HRS]

MS-HRS is a 24-item questionnaire covers societal resource use, regardless of the issue of reimbursement, as well as impact of the disease on work, family and leisure. With the help of this questionnaire a monetary value can be assigned to e.g. the stage of MS, a relapse or a therapy.

Baseline, month 6, month 12, month 18 and month 24
Fatigue Symptoms and Impact Questionnaire-RMS
Tijdsspanne: Baseline, month 3, month 6, month 12, month 18, month 24

Fatigue Symptoms and Impact Questionnaire-RMS [FSIQ-RMS]

The FSIQ-RMS comprises 20 items organized in a conceptual framework with 2 symptom domains (energy, muscle weakness) and 7 impact domains (daily activities, cognition, emotions, physical impact, self-care, sleep, social impact) in order to measure fatigue symptoms and impacts in relapsing multiple sclerosis.

A scoring algorithm standardizes scores on both the symptoms domain (daily and weekly) and impacts subdomains (weekly) to a 0 to 100 scale, with higher scores indicating more severe symptoms and impacts. There is no single summary score across the FSIQ-RMS instrument, but rather 1 symptoms score and 3 impacts subdomain scores.

Baseline, month 3, month 6, month 12, month 18, month 24
Patient Health Questionnaire 8 [PHQ-8]
Tijdsspanne: Baseline, month 3, month 6, month 12, month 18, month 24

The PHQ-8 is a valid diagnostic and severity measure for depressive disorders. It consists of eight items, each of which is scored 0 to 3, providing a 0 to 24 severity score. Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively.

Baseline, month 3, month 6, month 12, month 18, month 24
Generalized Anxiety Disorder Scale 7 [GAD-7]
Tijdsspanne: Baseline, month 3, month 6, month 12, month 18, month 24

The GAD-7 is a validated 7-item anxiety scale to diagnose generalized anxiety disorder. Each of the items is scored 0 to 3, providing a 0 to 21 severity score. Scores of 5, 10, and 15 represent cutpoints for mild, moderate, and severe anxiety, respectively

Baseline, month 3, month 6, month 12, month 18, month 24
Multiple Sclerosis Impact Scale 29 v2
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24

In this non-interventional study only the nine psychological items will be used to allow conclusions regarding the mental health status of patients with mildly active multiple sclerosis. In its version 2, each item of the MSIS-29 provides four response alternatives, which are rated as 1 to 4. Accordingly, the psychological scale will be described by a raw score between 9 and 36, which will be transformed into a final score between 0 (no impact) and 100 (extreme impact).

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24
Quality of Life in Neurological Disorders [NeuroQoL]
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24

n this non-interventional study the following items will be used: Anxiety, Depression, Ability to Participate in Social Roles and Activities, Positive Affect and Well-Being & Sleep Disturbance. Each response option is assigned a value (e.g.,1=Not at all) and total summed raw score for each respondent are calculated. The total raw score is then translated into a T-score for each participant by using conversion tables. These Tscore are standardized scores with a mean of 50 and a standard deviation (SD) of 10.

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24
MS Treatment Concerns Questionnaire [MSTCQ]
Tijdsspanne: Baseline, month 3, month 6, month 12, month 18, month 24

MS Treatment Concerns Questionnaire [MSTCQ] is used to assess participants' satisfaction with their treatment injections.

The MSTCQ includes 20 items pertaining satisfaction with the injection system (including issues related to use of the device and preparation of the medication for injection), and AEs related to the patient MS treatment.

All questions have a 5-point response choice, with the responses scored between 1-5. The MSTCQ scores are formed as the sum of all scores. The maximum total score is 100. Lower scores indicate a better state.

Baseline, month 3, month 6, month 12, month 18, month 24
Expanded disability status scale (EDSS)
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

EDSS is a widely used and accepted instrument to evaluate disability status at a given time and, longitudinally, to assess accumulation of disability in clinical studies in MS. The EDSS scale consists of scores in each of seven functional systems (FSs) and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The FSs are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel & Bladder, and Cerebral functions (Fatigue contributes)

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Time to onset of confirmed disability worsening (CDW)
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Time to onset of confirmed disability worsening (CDW) defined as an increase from baseline in EDSS sustained for at least 3 and 6 months, respectively

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Proportion of patients with confirmed disability worsening (CDW)
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Proportion of patients with confirmed disability worsening (CDW) defined as an increase from baseline in EDSS sustained for at least 3 and 6 months, respectively

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Time to onset of confirmed disability improvement (CDI)
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Time to onset of confirmed disability improvement (CDI) defined as a decrease from baseline in EDSS sustained for at least 3 and 6 months

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Proportion of patients with CDI
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Proportion of patients with CDI defined as a decrease from baseline in EDSS sustained for at least 3 and 6 months

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
T1 Gd-enhancing lesions per brain
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

T1 Gd-enhancing lesions per brain to be measured

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Annualized T2 lesion rate
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

New or enlarging T2 lesions per brain and per year (annualized T2 lesion rate)

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Presence of spinal cord lesions
Tijdsspanne: Baseline, month 3,month 6, month 9, month 12, month 15, month 18, month 21, month24

Proportion of patients with spinal cord lesions present

Baseline, month 3,month 6, month 9, month 12, month 15, month 18, month 21, month24
Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator.
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator. NEDA3 is defined as no 3mCDP, no confirmed MS relapse and no new or enlarging T2 lesions on any MRI scan compared to baseline

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Proportion of patients with no clinical disease activity and no discontinuation of current treatment due to AEs
Tijdsspanne: Up to 24 months

Proportion of patients with no clinical disease activity measured by relapse and disease progression and no discontinuation of current treatment due to AEs (excluding pregnancies) and lack of effectiveness

Up to 24 months
Annualized relapse rate
Tijdsspanne: Up to 24 months

Annualized relapse rate, defined as the number of confirmed Multiple Sclerosis relapses in a year.

Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection.

Up to 24 months
Time to first relapse
Tijdsspanne: Up to 24 months

Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection.

Up to 24 months
Proportion of relapse free patients
Tijdsspanne: Up to 24 months

Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection.

Up to 24 months
Serum NfL levels
Tijdsspanne: Baseline, month 6, month 12, month 18 and month 24

sNfL levels

Baseline, month 6, month 12, month 18 and month 24
Proportion of patients with low or elevated sNfL levels
Tijdsspanne: Baseline, month 6, month 12, month 18 and month 24

Proportion of patients with low or elevated sNfL levels

Baseline, month 6, month 12, month 18 and month 24
Association of selected effectiveness and PRO outcomes with sNfL levels
Tijdsspanne: Baseline, month 6, month 12, month 18 and month 24

Association of higher or lower sNfL concentrations with differences in e.g. disease activity, functional status, quality of life, and other PRO-based measures

Baseline, month 6, month 12, month 18 and month 24
Reasons for treatment decisions
Tijdsspanne: Up to 24 months

Number of participants by reasons for treatment decisions

Up to 24 months
Number of patients and reasons for discontinuation of treatment
Tijdsspanne: Up to 24 months

Number of patients and reasons for discontinuation of treatment classified by category:

  • efficacy (e.g. occurrence of relapse, evidence of disease activity in MRI)
  • safety and tolerability (e.g. injection-site reactions, influenza-like symptoms)
  • or convenience (e.g. inconvenient administration, frequency of injections)
Up to 24 months
Proportion of patients who continue to receive their subsequent treatment
Tijdsspanne: Up to 24 months

Proportion of patients who, at a given time over the observational period, continue to receive their subsequent treatment

Up to 24 months
Reasons for and number of treatment interruptions per patient
Tijdsspanne: Up to 24 months

Reasons for and number of treatment interruptions per patient to be collected

Up to 24 months
Duration of treatment interruptions per patient
Tijdsspanne: Up to 24 months

Duration of treatment interruptions per patient to be collected

Up to 24 months
Number of patients with treatment interruptions
Tijdsspanne: Up to 24 months

Number of patients with treatment interruptions to be collected

Up to 24 months
Proportion of drug-related adverse events (AEs)
Tijdsspanne: Up to 24 months

Proportion of drug-related adverse events (AEs) including those of special interest (main focus on injection site reactions such as scarring, skin reactions)

Up to 24 months
Persistence of drug-related adverse events (AEs)
Tijdsspanne: Up to 24 months

Persistence of drug-related adverse events (AEs) including those of special interest (main focus on injection site reactions such as scarring, skin reactions, influenza-like symptoms)

Up to 24 months
Specific safety assessment of injection related AEs
Tijdsspanne: Up to 24 months

Specific safety assessment of injection related AEs. (i.e. injection site reaction AEs vs. injection systemic reaction AEs) summarized by providing the number and percentage of patients with each of the symptoms and pre-specified grouping of symptoms as well as overall.

Up to 24 months
Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons
Tijdsspanne: Up to 24 months

Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons

Up to 24 months
Proportion of sites that share the standardized MRI report form with their radiological colleagues
Tijdsspanne: Baseline, month 6, month 12, month 18 and month 24

Proportion of sites that share the standardized MRI report form with their radiological colleagues

Baseline, month 6, month 12, month 18 and month 24
Proportion of standardized MRI report forms and conventional radiologists' reports
Tijdsspanne: Baseline, month 6, month 12, month 18 and month 24

Proportion of standardized MRI report forms and conventional radiologists' reports

Baseline, month 6, month 12, month 18 and month 24
Effect of standardized MRI report form on completeness of lesion documentation
Tijdsspanne: Baseline, month 6, month 12,1 month 8 and month 24

Proportion of complete MRI lesion documentation using the standardized MRI form versus non-standardized documentation.

Baseline, month 6, month 12,1 month 8 and month 24
Physician's view on added value of standardized MRI report form over conventional radiologists' reports
Tijdsspanne: Baseline, month 6, month 12, month 18 and month 24

Proportion of physicians who rate the added value of the standardized MRI report form higher than that of conventional radiologists' reports

Baseline, month 6, month 12, month 18 and month 24
Proportion of patients and physicians that intend to view and use PRO and sNfL results to support patient-physician dialogue
Tijdsspanne: Month 6,month 12, month 18 and month 24

Proportion of patients and physicians that intend to view and use PRO and sNfL results to support patient-physician dialogue

Month 6,month 12, month 18 and month 24
Proportion of patients that access their PRO and sNfL result visualizations at least once every 6 months
Tijdsspanne: Month 6,month 12, month 18 and month 24

Proportion of patients that access their PRO and sNfL result visualizations at least once every 6 months

Month 6,month 12, month 18 and month 24
Perceived value of PRO and sNfL result visualizations from the perspective of both patient and treating physician on patient-physician dialogue and shared decision making
Tijdsspanne: Month 6,month 12, month 18 and month 24

Proportion of patients and physicians who perceive an added value of PRO and sNfL result visualizations on patient-physician dialogue and shared decision making

Month 6,month 12, month 18 and month 24
Age of male and female participants
Tijdsspanne: Baseline

Age

Baseline
Number of previous MS relapses of male and female participants
Tijdsspanne: Baseline

Number of MS relapses in the 24 months prior baseline

Baseline
Serum NfL levels of male and female patients
Tijdsspanne: Baseline, month 6, month 12, month 18 and month 24

sNfL levels

Baseline, month 6, month 12, month 18 and month 24
Proportion of male and female patients who continue to receive their baseline treatment
Tijdsspanne: Month 12, Month 24

Proportion of male and female patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)]

Month 12, Month 24
Annualized relapse rate of male and female patients
Tijdsspanne: Up to 24 months

Annualized relapse rate, defined as the number of confirmed Multiple Sclerosis relapses in a year of male and female participants

Up to 24 months
Reasons for treatment decisions of male and female patients
Tijdsspanne: Up to 24 months

Number of male and female participants by reasons for treatment decisions

Up to 24 months
Quality of Life in Neurological Disorders [NeuroQoL] of male and female patients
Tijdsspanne: Baseline, month 3, month 6, month 9, month 12, month15, month 18, month 21 and month 24

T-scores of male and female patients.

  • Anxiety: Score range from 36.4 to 76.8
  • Depression: Score range from 36.9 to 75.0
  • Sleep Disturbance: Score range from 32.0 to 84.2
  • Ability to Participate in Social Roles and Activities: Score range from 24.1 to 60.2
  • Positive Affect and Well-Being: Score range from 26.3 to 68.0 For positive domains (e.g. Well-Being): higher score = better QoL. For symptom domains (e.g. Anxiety): higher scores = worse symptoms
Baseline, month 3, month 6, month 9, month 12, month15, month 18, month 21 and month 24

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 mei 2022

Primaire voltooiing (Geschat)

30 mei 2029

Studie voltooiing (Geschat)

30 mei 2029

Studieregistratiedata

Eerst ingediend

19 april 2022

Eerst ingediend dat voldeed aan de QC-criteria

19 april 2022

Eerst geplaatst (Werkelijk)

25 april 2022

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

13 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren